…this is the best educational website for students and teachers, providing FREE access to teaching materials, e-lesson notes, online study, and a hub to access latest news and job vacancies. Not yet a member? Signup
The COVID-19 pandemic has created an instant market for vaccine development. Around $1 billion of U.S. taxpayer funds have already been given to Big Pharma to develop the much coveted COVID-19 mRNA vaccine, a new class of vaccines that have never before been successfully developed. ($450 million to Johnson & Johnson in March, and $483 million to Moderna Therapeutics in April.)
And this is all just for starters, as over 100 COVID-19 vaccines are currently in development by most of the world’s largest pharmaceutical companies. The CARES Act signed into law on Mar. 27, 2020 allocates $27 billion for COVID-19 vaccine development, just in the U.S. alone.
And if that wasn’t enough, earlier this week (May, 2020) President Trump seemingly gave a blank check to spend as much as possible to fast track a COVID-19 vaccine through “Operation Warp Speed,” a coalition of scientists, government officials, military agencies, and private companies led by Alex Azar, the Health and Human Services Secretary, and Mark Esper, the Defense Secretary.
Their goal: to deliver 300 million doses of coronavirus vaccine from November to December 2020 and another 300 million by January 2021. (Source.)
So just by starting to research a COVID-19 vaccine, the already lucrative pharmaceutical industry just became the all-time most profitable industry on the planet.
As pharmaceutical companies compete with each other to get a COVID-19 vaccine to market, there was initial skepticism that an mRNA vaccine could be developed anytime soon. Projections were that it would take about 5 years, and even then only with a small chance of success.
Now, as we saw earlier this week with the announcement of the new “Operation Warp Speed” project, the projections are to produce enough vaccines to be able to inject all 350 million citizens of the United States by the end of 2020.
And on May 1st this week Moderna Therapeutics announced a partnership with Lonza manufacturing to start producing 1 billion COVID-19 vaccines a year.
Moderna Therapeutics is partnering with Dr. Anthony Fauci of the National Institutes of Health (NIH), who also has close ties to Bill Gates.
Bill Gates said in an interview this week that 7 billion vaccine doses are needed to end the COVID-19 pandemic, which is about the number of people currently living on the planet.
Will the entire world’s population just volunteer to get this vaccine, or are the drug companies counting on the fact that they will become mandatory?
The world’s largest manufacturer of vaccines, the Serum Institute of India, which produces 1.5 billion vaccine doses a year for an array of diseases, said it was not going to wait for approval of a COVID-19 vaccine, but would start manufacturing them immediately, starting with 40 million doses. They are currently working with the the Oxford Vaccine Group. (Source.)
It would seem that pharmaceutical companies manufacturing a COVID-19 vaccine are banking on the fact that the World Health Organization will recommend that they be mandatory.
Will the U.S. comply?
Is President Trump is the Key to Mandatory COVID-19 Vaccines in the U.S.?
There are good reasons why vaccine industry insiders balked at the idea of developing an mRNA vaccine so quickly initially. They have tried to develop them in the past, with dismal results. They were unsuccessful in trying to develop this kind of vaccine for other coronaviruses, like SARS and MERS.
Dr. Fauci and the NIH, working together with Bill Gates, also previously had dismal results in developing this kind of vaccine for HIV/AIDS.
But all of that has now changed with the world-wide “pandemic” of COVID-19.
President Trump can now eliminate safety tests normally required for FDA approval of drugs and vaccines, by invoking the “Emergency Use Authorization” authority which “allows FDA to help strengthen the nation’s public health protections against CBRN threats by facilitating the availability and use of MCMs needed during public health emergencies.”
According to the FDA website:
Under section 564 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), the FDA Commissioner may allow unapproved medical products or unapproved uses of approved medical products to be used in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions caused by CBRN threat agents when there are no adequate, approved, and available alternatives.
Section 564 of the FD&C Act was amended by the Project Bioshield Act of 2004 and was further amended by the Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 (PAHPRA), the 21st Century Cures Act of 2016, and Public Law 115-92 of 2017.
President Trump invoked this authority this week (May, 2020) in directing the FDA to approve the anti-viral drug remdesivir, which was previously abandoned as a treatment for Ebola.
“I’m pleased to announce that Gilead now has a EUA (emergency use authorization) from the FDA for remdesivir — and you know what that is, because that’s been the hot thing also in the papers and in the media for the last little while,” the president said.
FDA Commissioner Stephen Hahn confirmed the authorization “was issued today.” (Source.)
This is like a dream come true for pharmaceutical companies. A pandemic allows them to secure government funds to research new drugs.
It allows them to bypass normal FDA safety testing with legal immunity should things go wrong and people are injured or die from the side effects.
Then the government, who paid for the research and development, ends up spending more of your taxpayer funds to purchase these vaccines through the CDC, and then requires the American population to receive them, while selling the excess vaccines produced that the American public does not use to the World Health Organization to be mandated upon citizens of other countries.
With the announcement earlier this week that Moderna Therapeutics has developed a partnership with Lonza manufacturing to start producing 1 billion COVID-19 vaccines a year, it would seem that they are the leading candidate at this point to benefit the most, especially since they are working in partnership with Dr. Anthony Fauci, a member of President Trump’s Coronavirus task force team.
The Moderna – Lonza partnership was huge news this week, as Fauci said back in February that even if they had a vaccine that would work, it would be difficult to produce so many so quickly:
Production would require an amount of time that’s as “problematic” as developing the shot itself, Fauci said. (Source.)
Fauci also allegedly stated that once Moderna reached phase 2 testing of the vaccine, that it would be tested in China, suggesting that he is still working closely with the World Health Organization, and looking at supplying his COVID-19 vaccine to the entire world. (Source.)